Inogen, Inc. — FY 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016; filed February 28, 2017. Inogen develops, manufactures and sells portable oxygen concentrators and also rents oxygen equipment directly to patients. The filing reports annual results and selected quarterly data, including Q4 2016.
Financial performance
| Metric | FY 2016 | FY 2015 | Change |
|---|---|---|---|
| Revenue | $202.8 million | $159.0 million | +27.6% |
| Sales revenue | $168.2 million | $113.6 million | +48.0% |
| Rental revenue | $34.7 million | $45.4 million | -23.6% |
| Gross profit / gross margin | $97.3 million / 48.0% | $76.3 million / 48.0% | Gross profit +27.6% |
| Operating income | $22.9 million | $15.1 million | +51.9% |
| Net income / diluted EPS | $20.5 million / $0.97 | $11.6 million / $0.56 | Net income +77.1% |
| Cash from operating activities | $31.0 million | $38.2 million | Down $7.1 million |
Sales growth reflected higher domestic and international business-to-business demand and direct-to-consumer sales. The company sold approximately 92,000 systems, up from 56,600. Sales gross margin improved to 49.4% from 45.8%, while rental gross margin fell to 41.2% from 53.3%, reflecting reimbursement pressure and higher rental revenue adjustments.
Q4 revenue was $50.9 million, compared with $40.4 million in Q4 2015; net income was $5.3 million, compared with $3.9 million. The filing does not provide a standalone Q4 cash-flow figure.
Cash, liquidity and debt
- Year-end cash and cash equivalents were $92.9 million; marketable securities were $21.0 million. Working capital was $138.7 million.
- Operating cash flow was $31.0 million, despite higher net income, as accounts receivable, inventory and other current assets absorbed cash. Net accounts receivable rose to $30.8 million from $19.9 million.
- No debt was outstanding at year-end. The company had $15.0 million available under its revolving credit facility and reported compliance with its financial covenants.
- Purchase obligations totaled $44.8 million, mostly due within one year.
Material changes, outlook and unusual items
- Revenue mix shifted toward product sales: sales reached 82.9% of revenue, versus 71.5% in 2015; rentals fell to 17.1% from 28.5%.
- Management expects rental revenue to decline in 2017, citing reimbursement-rate reductions and continued emphasis on sales over new rentals. It expects sales and marketing, R&D and general and administrative expenses to rise; the filing provides no formal numerical revenue or earnings guidance.
- The Cures Act retroactively restored certain Medicare reimbursement rates for part of 2016, adding a non-recurring $2.0 million to Q4 rental revenue. Related additional payments were expected in Q2 and Q3 2017. Medicare rates returned to adjusted fee-schedule levels beginning January 1, 2017.
- Early adoption of stock-compensation accounting guidance reduced 2016 income-tax expense by approximately $6.0 million and increased opening 2016 retained earnings by $12.2 million. The 9.7% effective tax rate is therefore not a straightforward measure of the ongoing tax burden.
- The Inova Labs patent settlement produced a $1.13 million gain recorded in general and administrative expense. A California wage-and-hour matter was settled for approximately $0.9 million, paid in December.
- Pending intellectual-property litigation includes claims by Separation Design Group and CAIRE; Inogen denies the allegations and says it will contest them. Management reported no reserve for lawsuits and no expected material adverse effect from other proceedings.
- Medicare competitive bidding, lower reimbursement, the 36-month rental payment cap and prior-authorization proposals pose risks to rental economics. About 17.1% of rental patients were capped at year-end, up from 14.1% a year earlier.
- Management planned a Cleveland-area facility and a European customer-support site in 2017, with added costs; the Ohio expansion was expected to add approximately 240 employees over three years. CEO Raymond Huggenberger was to retire effective March 1, 2017, with President and COO Scott Wilkinson appointed CEO.
Investor verification priorities
- Assess the sustainability of sales growth and sales margins against the sharp contraction in rental revenue and rental margins.
- Separate recurring earnings from the $2.0 million reimbursement catch-up, settlement gain and approximately $6.0 million stock-compensation tax benefit.
- Track Medicare and private-payor rate changes, competitive-bidding access, capped-patient trends and the timing and collection of Cures Act payments.
- Review receivables growth, allowance estimates, customer concentration and operating cash conversion; one private-label customer exceeded 10% of revenue, and one customer represented $9.8 million of year-end net receivables.
- Monitor the SDGIP and CAIRE cases, execution costs for planned facilities and hiring, and the effect of the leadership transition.